BEIJING TIDE PHARM
GenericsBEIJING TIDE PHARM is a generic drug manufacturer focused on Respiratory, Oncology, Gastroenterology.
BEIJING TIDE PHARM at a Glance
- Growing R&D activity with 7 trials in last 2 years
BEIJING TIDE PHARM's Key Drugs
BEIJING TIDE PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
BEIJING TIDE PHARM's Recent FDA Approvals
New NDA/BLA approvals for BEIJING TIDE PHARM over the last two years — novel drugs only, excluding generics and label supplements.
BEIJING TIDE PHARM's Therapeutic Areas
BEIJING TIDE PHARM's approved drugs and pipeline span 3 therapeutic areas, led by Respiratory and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BEIJING TIDE PHARM's Top Competitors
BEIJING TIDE PHARM's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BEIJING TIDE PHARM Pipeline Snapshot
BEIJING TIDE PHARM has 4 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 3 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/1 completed
- • Speed: N/A months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2021-10-14
- Latest
- 2021-10-14
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges